18F-FDG–avid at 3 mo | 18F-FDG–avid at 6 mo | |||||
PET-5PS | + | − | Total | + | − | Total |
18F-FDG–avid 3 mo later | ||||||
+ | 119 | 13 | 132 | 63 | 4 | 67 |
− | 16 | 142 | 158 | 2 | 138 | 140 |
Total | 135 | 155 | 290 | 65 | 142 | 207 |
PPV, 88% | NPV, 92% | PPV, 97% | NPV, 97% |
We evaluated glucose metabolism within 290 Hodgkin lesions at baseline and every 3 mo after anti-PD1 initiation. PET-5PS had excellent NPV and PPV.